Back icon Back
Freenome

Freenome

Company

By Sriparna Roy
Feb 15 (Reuters) – Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple early-stage cancers. The company did not disclose the valuation at which the funds were raised.

https://www.reuters.com/business/healthcare-pharmaceuticals/cancer-test-firm-freenome-raises-254-mln-fresh-funding-2024-02-15/

Date

Feb 15, 2024

Category

healthcare

Lead investor

Country Icon Roche Venture Fund

Stage

Series E

Size

$254M

Explore similar Investments to Freenome

Company
Size
Date
Lead Investor
Press
Browserbase

Browserbase

Company
$21M
Oct 29, 2024
Investor Kleiner Perkins
Source
Moonvalley

Moonvalley

Company
$70M
Nov 18, 2024
Investor General Catalyst
Source
Tailscale

Tailscale

Company
$160M
Apr 8, 2025
Investor Accel
Source
Stainless

Stainless

Company
$25M
Dec 10, 2024
Investor a16z
Source
Legora

Legora

Company
$80M
May 21, 2025
Investor General Catalyst
Source
Better Auth

Better Auth

Company
$5M
Jun 25, 2025
Investor Peak XV
Source
Captions

Captions

Company
$100M
Jul 9, 2024
Investor a16z
Source
All Hands

All Hands

Company
$5M
Sep 5, 2024
Investor Menlo Ventures
Source
Vanta

Vanta

Company
$150M
Jul 23, 2025
Investor Goldman Sachs
Source
Rainforest

Rainforest

Company
$20M
Jun 26, 2024
Investor Matrix Partners
Source
Lumos

Lumos

Company
$35M
May 23, 2024
Investor Scale Venture Partners
Source
Port IO

Port IO

Company
$35M
Oct 15, 2024
Investor Accel
Source

Startups, venture funds
& everything in between.

Explore verified companies, top VCs, and practical guides built to help you raise, invest, and grow faster.
Made by Omnius. For builders, by builders.
Venture Funds Startups Investments Events Programs Case Studies Interviews & Lectures Reports & Publications